Intermittent Fasting

Fasting affects insulin levels and inflammation, both of which can hinder cancer cell growth. While fasting shows significant promise for hormonal regulation, its impact on bone density is a primary area of concern that requires a “nutrient-first” approach.

• The Potential Benefits for HR+ Cancer Insulin Regulation: HR+ breast cancer cells often have receptors for insulin-like growth factor (IGF-1). Fasting helps lower circulating insulin, which may “starve” the environment that helps these cells thrive.
• Reduced Inflammation: Intermittent Fasting can lower C-reactive protein (CRP), a marker of inflammation. Lower inflammation is generally linked to better outcomes and reduced risk of recurrence.
• Weight Management: Since body fat produces estrogen (the “fuel” for HR+ cancer), Intermittent Fasting can be an effective tool to maintain a healthy weight and reduce that extra estrogen production.
• The “13-Hour” Study: A notable study published in JAMA Oncology found that breast cancer survivors who fasted for fewer than 13 hours per night had a 36% higher risk of recurrence compared to those who fasted for 13 hours or more.

Fasting flushes toxic fat from organs and arteries – Dr. Pradip Jamnadas, MD

Popular Methods:

Most oncologists who support fasting recommend starting with a 12 to 13-hour overnight fast. It is less stressful on the body than longer fasts, doesn’t usually interfere with medication, and aligns with the most promising breast cancer-specific research. Focus on early time-restricted feeding (eTRF), ending meals by 6 PM.

• The 13-Hour Overnight Fast: This is the most “doable” and researched version for breast cancer. Simply stop eating at 7:00 PM and don’t eat again until 8:00 AM the next day. This provides metabolic benefits without the extreme nutrient restriction that threatens bone density.
• Circadian Rhythm Fasting or Early Time-Restricted Feeding (eTRF): This involves eating during daylight hours and stopping once the sun goes down, which aligns with your body’s natural metabolic clock. This involves consuming calories early in the day (e.g., 8 a.m. to 2 p.m. or 4 p.m.) and fasting for 14–18 hours. It is more effective than later eating for weight loss, improving insulin sensitivity, reducing blood pressure, and lowering inflammation.
• The 16:8 Method: Eat all meals within an 8-hour window (e.g., 11:00 AM to 7:00 PM) and fast for 16 hours.

Critical Note:

• Bone Density Risk: Potential for lower Calcium/Vitamin D/Protein. Use a wider window (10-12 hours) to fit in nutrients. Ensure your eating window includes at least two distinct meals with 30g+ of protein and 500mg of calcium to maximize absorption.
• Muscle Loss: It is vital to eat enough protein during the “eating window.” If already at risk for bone and muscle loss due to hormone therapy, fasting leads to muscle wasting (sarcopenia). To counteract potential bone loss from fasting, “osteogenic loading” (weight-bearing exercise) is essential during your fed states.
• Many HR+ treatments (like Aromatase Inhibitors) already increase the risk of bone loss. Before starting any fasting regimen, it is vital to check your DXA scan results and Vitamin D levels with your oncologist to ensure your bones can handle the metabolic shift.